AMRN logo

AMRN
Amarin Corp - ADR

30,473
Mkt Cap
$315.74M
Volume
43,173.00
52W High
$20.90
52W Low
$9.98
PE Ratio
-9.29
AMRN Fundamentals
Price
$15.05
Prev Close
$14.84
Open
$14.82
50D MA
$14.66
Beta
1.02
Avg. Volume
67,538.46
EPS (Annual)
-$1.87
P/B
0.70
Rev/Employee
$2.68M
$7.15
Loading...
Loading...
News
all
press releases
TBPH Q1 Earnings Beat Amid Strategic Restructuring & Pipeline Hurdle
Theravance Q1 earnings top estimates as collaboration revenues grow, while restructuring and cost cuts aim to drive $60-$70M annualized cash flow.
Zacks·22h ago
News Placeholder
More News
News Placeholder
VRTX's Alyftrek, Journavx & Casgevy See Strong Momentum in Q1 Earnings
Vertex's new drugs are gaining momentum as Alyftrek tops $1 billion in sales and Journavx prescriptions accelerate.
Zacks·22h ago
News Placeholder
Xenon Q1 Earnings Match Estimates, Pipeline Development in Focus
XENE's Q1 loss matches estimates, while phase III azetukalner data, cash growth and late-stage pipeline progress stay in focus.
Zacks·23h ago
News Placeholder
Kodiak's Q1 Loss Wider Than Expected, Pipeline Development in Focus
KOD posts a wider Q1 loss as research & development spending rises, while positive phase III Zenkuda data accelerate the regulatory plans.
Zacks·23h ago
News Placeholder
BEAM's Q1 Loss Wider Than Expected, Revenues Beat Estimates
Beam Therapeutics Q1 revenues beat estimates as its gene-editing pipeline advanced, with key updates across the SCD, AATD and PKU programs.
Zacks·23h ago
News Placeholder
PBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance Raised
Puma Biotechnology beats Q1 earnings and revenue estimates while raising its 2026 outlook.
Zacks·23h ago
News Placeholder
IOVA Q1 Earnings Match Estimates, Sales Miss, Stock Down 13%
Iovance matches Q1 earnings estimates, but weaker-than-expected Amtagvi and Proleukin sales sent shares down 13% despite revenue growth.
Zacks·1d ago
News Placeholder
Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%
INSM stock plunges 23% after Q1 sales miss estimates despite 230% revenue growth and strong Brinsupri uptake.
Zacks·1d ago
News Placeholder
Viatris Q1 EPS Beats Estimates, Revenues up 8% Driven by Greater China
VTRS beats Q1 estimates as revenues climb 8% on strong Greater China and brands sales, while management reaffirms 2026 guidance.
Zacks·2d ago
News Placeholder
ADMA Q1 EPS Jumps 73% Y/Y, Revenues Slip, 2026 View Down
ADMA cuts its 2026 outlook after Q1 revenues slip amid IG market pressure, though Asceniv demand and margins stay strong.
Zacks·2d ago
<
1
2
...
>

Latest AMRN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.